Story perspectives
FDA Promises Swift Medicine Approvals Amid Controversy
6/18/2025
50 3
1 of 1
Story summary
- The FDA is set to accelerate the review process for new medicines, promising decisions within one to two months to meet U.S. health priorities. Commissioner Marty Makary advocates for this swift approach, reminiscent of the rapid COVID-19 vaccine approvals. Yet, this push for speed clashes with the stricter vaccine standards outlined by Health Secretary Robert F. Kennedy Jr.
